Support teaching, research, and patient care.
Dr. Jeremy Heit is an Associate Professor of Radiology and of Neurosurgery and the Chief of Neuroimaging and Neurointervention at Stanford University. Dr. Jeremy Heit is a neurointerventional surgeon (neurointerventional radiologist) who specializes in treating stroke, brain aneurysms, brain arteriovenous malformations, brain and spinal dural arteriovenous fistulae, carotid artery stenosis, vertebral body compression fractures, and congenital vascular malformations. Dr. Heit treats all of these conditions using minimally-invasive, image-guided procedures and state-of-the-art technology.Dr. Heit’s research seeks to understand the genetic, developmental, and pathophysiologic basis of cerebrovascular disease. In addition, his group is developing new minimally invasive, image-guided treatments for ischemic and hemorrhagic stroke. He has authored over 150 publications and is an investigator on multiple grants, including the CRISP 2 and DEFUSE 3 studies. He is the co-PI of the NIH-funded PRECISE basilar thrombectomy study.For more information about Dr. Heit's research lab, please visit: www.heitlab.com
Our research seeks to advance our understanding of cerebrovascular disease and to develop new minimally invasive treatments for these diseases. We study ischemic and hemorrhagic stroke, cerebral aneurysms, delayed cerebral ischemia, cerebral arteriovenous malformations (AVMs), dural arteriovenous fistulae, and other vascular diseases of the brain. We use state-of-the-art neuroimaging techniques to non-invasively study these diseases, and we are developing future endovascular technologies to advance neurointerventional surgery.www.heitlab.com
Ruptured Aneurysms Treated With Hydrogel Coils
To determine safety and occlusion rates when second-generation hydrogel coils are used in the
treatment of ruptured intracranial aneurysms.
View full details
PHIL in the Treatment of Intracranial dAVF.
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous
Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with
qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical
management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days
when compared to medical management alone in appropriately selected subjects with the Target
mismatch profile and an MCA (M1 segment) or ICA occlusion who can be randomized and have
endovascular treatment initiated between 6-16 hours after last seen well.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .